Brief: Cantargia Reports Progress And Strong Biomarker Data From Phase I Clinical Trial With Can10

Cantargia AB

09/08/2024 10:21

Aug 9 (Reuters) - Cantargia AB  CANTA.ST :
    * CANTARGIA REPORTS PROGRESS AND STRONG BIOMARKER DATA FROM
PHASE
I CLINICAL TRIAL WITH CAN10
    * NEW PHARMACODYNAMIC BIOMARKER RESULTS FROM STUDY CONFIRM
THAT
CAN10 POTENTLY INHIBITS  ACTIVITY OF INFLAMMATORY IMMUNE CELLS
AFTER SINGLE DOSE

Source text for Eikon:  ID:nMFN84f18P 
Further company coverage:  CANTA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;  +48 58 769 66 00;))